Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of October 2019, specifically dated October 7, 2019. The filing discloses a significant corporate governance agreement entered into with Capital Point Ltd. to resolve ongoing disputes and secure shareholder support.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a contractual agreement regarding financial advisory services and litigation resolution rather than operational financial performance.
Material Changes and Agreement Details
- Advisory Agreement: Can-Fite retained Capital Point for financial advisory services with a fee structure of 5% of amounts raised or securities issued in future transactions, capped at $1.3 million.
- Litigation Resolution: Both parties agreed to promptly seek the dismissal of all pending litigation between them.
- Shareholder Support: Capital Point agreed to withdraw notices to call a shareholders' meeting and to vote all its shares in favor of the Company's board proposals at the 2019 and 2020 annual meetings.
- Standstill Provisions: Capital Point agreed to a five-year standstill restricting share purchases, proxy contests, and the calling of special meetings.
- Additional Terms: The agreement includes mutual releases, non-disparagement, and confidentiality clauses.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors beyond the context of the resolved litigation. The primary contingency addressed is the cessation of legal disputes and the stabilization of shareholder relations through the standstill agreement.
Key Facts for Investor Verification
- Verify the status of the pending litigation between Can-Fite and Capital Point to confirm dismissal.
- Monitor future capital raising activities to assess if the 5% advisory fee (up to $1.3 million) is triggered.
- Confirm Capital Point's voting record at the 2019 and 2020 annual shareholders' meetings.
- Review the Company's subsequent filings for any updates on the financial impact of the advisory agreement.